Countervail Corporation


Countervail corporation is awarded $346,000 for phase 1 of fast track SBIR Grant from the National Institutes of Health for studies of nerve gas antidote

Following NIH peer review of a grant proposal, Countervail was awarded the first phase of a 4-year fast track SBIR grant. Funds will used to validate proof of concept for the use of galantamine as a pre-treatment medical countermeasure for soman, sarin and VX poisoning.